The UK DNA Diagnostics Market was valued at $762.2 Million in 2024 and projected to reach to $1262.5 Million by 2029, representing a compound annual growth rate of 10.6%. The UK DNA Diagnostics Market is poised for sustained growth through 2029, driven by NHS genomic initiatives, rising consumer awareness of genetic testing benefits, and increasing integration of DNA diagnostics into routine clinical practice.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK DNA Diagnostics Market is valued at £762.2 million in 2024, with a robust CAGR of 10.6% projected through 2029, significantly outpacing the global growth rate of 9.7%.
Increasing NHS investment in genomic medicine and the expansion of the National Genomic Medicine Service are driving widespread adoption of DNA diagnostics across UK healthcare systems.
UK patients and healthcare providers are increasingly embracing precision medicine approaches, with genetic testing becoming integral to cancer diagnosis, rare disease identification, and personalized treatment planning.
The UK's sophisticated healthcare ecosystem, regulatory framework, and strong research institutions create an ideal environment for DNA diagnostic innovation and market expansion.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | HPV (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 9.7% from 2024 to 2029 |
| Largest Segment | BLOOD, PLASMA, AND SERUM (Specimen) |
| Market Size Base Year (Billions) | ~USD 13.34 (2024) |
| Revenue Forecast (Billions) | ~USD 21.2 (2029) |
| Segments Covered | Offering, Technology, Specimen, Application, Type, End User |
6 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| DIAGNOSTIC LABORATORIES | 361.6 | 397.2 | 439.6 | 487.8 | 543.3 | 607.4 | 680.8 | 765.2 | 11.7 |
| HOSPITALS & CLINICS | 179.1 | 194.1 | 211.7 | 231.5 | 253.8 | 279.1 | 307.5 | 339.5 | 9.9 |
| OTHER END USERS | 98.9 | 104.4 | 110.9 | 118.2 | 126.4 | 135.7 | 146.1 | 157.7 | 7.3 |
| TOTAL | 639.6 | 695.7 | 762.2 | 837.5 | 923.6 | 1022.2 | 1134.5 | 1262.5 | 10.6 |
The UK DNA Diagnostics Market is valued at £762.2 million in 2024, with expectations to grow to £1,262.5 million by 2029.
The UK market is projected to grow at a CAGR of 10.6% from 2024 to 2029, exceeding the global average of 9.7%.
Key applications include oncology diagnostics, rare disease identification, prenatal screening, and pharmacogenomics, all supported by NHS integration initiatives.
The NHS Genomics Education Programme and integration of genomic testing into standard clinical pathways are accelerating adoption and market growth across the UK healthcare system.
The UK Health Security Agency's supportive regulatory framework and post-Brexit autonomy enable faster innovation cycles and market entry for diagnostic providers.
To determine the current size of the DNA diagnostics market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.
The four steps involved in estimating the market size are
Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (like D&B Hoovers, Bloomberg Business, and Factiva), white papers, certified publications, articles by well-known authors, annual reports, press releases, and investor presentations of companies.
During the primary research phase, a comprehensive approach was adopted, involving interviews with a diverse array of sources from both the supply and demand sides. These interviews aimed to gather qualitative and quantitative data essential for compiling this report. Primary sources primarily comprised industry experts spanning core and related sectors, as well as favored suppliers, manufacturers, distributors, service providers, technology innovators, and entities associated with all facets of this industry's value chain. In-depth interviews were meticulously conducted with a range of primary respondents, including key industry stakeholders, subject-matter authorities, C-level executives representing pivotal market players, and industry advisors. The objective was to obtain and authenticate critical qualitative and quantitative insights and to evaluate future potentialities comprehensively.
A breakdown of the primary respondents is provided below:

Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
Roche Diagnostics Ltd. |
Area Sales Manager |
|
Danaher Corporation |
General Manger |
|
Thermo Fisher Scientific Inc. |
Consultant |
All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the DNA diagnostics market was also split into various segments and subsegments at the region and country level based on:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
DNA diagnostic tests detect and analyze variations in the sequence, structure, or expression of deoxyribonucleic acid (DNA) to diagnose diseases or medical conditions. This includes identifying indications caused by specific pathogens or determining genetic carrier status.
DNA diagnostic techniques can detect numerous diseases, such as cancer, viral diseases, and myogenic disorders. They are also employed in prenatal diagnostics and clinical diagnostic confirmation.
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for the report:
Further breakdown of the DNA diagnostics market into specific countries/regions in Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries.
Detailed analysis and profiling of additional market players (up to Five), inclusive of:
Note: Some companies are privately owned, and their revenues are unavailable in the public domain. Hence, revenues for privately owned companies will not be included in their profile. In addition, company developments that are not reported in the public domain will not be included.
Full forecast, segment splits, and company analysis for all DNA Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report